败走童颜针又陷财务造假 *ST苏吴退市落定

Core Viewpoint - The company *ST Suwu has been delisted due to long-term financial fraud and information disclosure violations, with significant implications for its future operations and survival in the market [1][4]. Group 1: Delisting and Financial Misconduct - *ST Suwu received a delisting notice from the Shanghai Stock Exchange, with its stock entering a delisting adjustment period on December 9 [1]. - The China Securities Regulatory Commission (CSRC) found that *ST Suwu concealed its actual controller and inflated its operating income by over 1.771 billion yuan through related party transactions since 2018 [1][4]. - Approximately 1.693 billion yuan of the company's funds were non-operationally occupied by related parties, nearly depleting its core assets [1][4]. Group 2: Financial Performance and Business Challenges - The company's revenue significantly declined by 38.85% year-on-year in the first three quarters of 2025, with a net loss expanding to 87.468 million yuan [1][7]. - The "Tongyan Needle" business, which previously contributed over 40% of gross profit, has been halted due to ownership disputes, further exacerbating the company's financial struggles [1][7]. - The traditional pharmaceutical segment also performed poorly, with a revenue drop of 55.79% year-on-year in the same period [7]. Group 3: Regulatory Actions and Penalties - The CSRC issued a fine of 10 million yuan to *ST Suwu and imposed a 1.5 million yuan fine on its actual controller, who is also banned from the securities market for 10 years [4]. - The company has been under investigation since February 2023 for information disclosure violations, leading to a series of warnings and penalties [3][4]. Group 4: Future Outlook and Market Position - With the delisting, *ST Suwu faces severe challenges in resource liquidity and credit collapse, losing its financing capabilities in the capital market [8]. - The company has only about 49.1947 million yuan in cash as of the end of the third quarter of 2025, facing immense pressure on its cash flow [8]. - The ongoing dispute over the agency rights for the "AestheFill" product remains unresolved, further complicating the company's recovery prospects [6][9].